ACT Capital Management’s TG Therapeutics TGTX Stock Holding History

ACT Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8M	Buy	251,025 +2,000	+0.8%	+$81.9K	9.01%	2
2026 Q1	$8.27M	Sell	249,025 -19,850	-7%	-$592K	6.5%	5
2025 Q4	$8.02M	Buy	+268,875	New	+$8.78M	6.48%	5
2022 Q1	–	Sell	-33,900	Closed	-$644K	–	96
2021 Q4	$644K	Sell	33,900 -26,100	-44%	-$678K	0.47%	40
2021 Q3	$2M	Buy	60,000 +5,000	+9%	+$155K	1.04%	20
2021 Q2	$2.13M	Buy	+55,000	New	+$2.16M	1.1%	21

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

ACT Capital Management's TGTX Position: Q2 2026 in Review

ACT Capital Management increased its TG Therapeutics (TGTX) stake by 0.8% in Q2 2026, buying an estimated $81.9K and bringing the position to 251,025 shares worth $13.8M. The position accounts for 9.01% of the portfolio, ranked #2.

ACT Capital Management first reported a position in TGTX in Q2 2021 and has held it in 6 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

ACT Capital Management held 251,025 shares of TG Therapeutics worth $13.8M as of Q2 2026.
ACT Capital Management bought 2,000 TG Therapeutics shares in Q2 2026, an estimated $81.9K.
TG Therapeutics made up 9.01% of ACT Capital Management's portfolio in Q2 2026, its #2 holding.
ACT Capital Management first reported a position in TG Therapeutics in Q2 2021 and has held it in 6 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.